Fineline Cube

Follow:
14475 Articles
CompanyMedical Device

Gaush Meditech Secures CE Mark for Corneal Confocal Microscope, Paving Way for EU Commercial Launch

CompanyDeals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
Others

Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech

CompanyDeals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

CompanyDeals

Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio

CompanyDrug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
CompanyDeals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

CompanyDrug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
CompanyMedical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
CompanyDrug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

CompanyDeals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

CompanyDrug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC